3.987

5.00% 0.187

Sab Biotherapeutics Inc (SABS)

Overview News Price History Financials Discussions Forecast

Sab Biotherapeutics Inc stock is traded at $3.987, with a volume of 426.60K. It is up +5.00% in the last 24 hours and up +25.47% over the past month. SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Previous Close:

$3.80

Open:

$3.82

24h Volume:

426.60K

Relative Volume:

1.58

Market Cap:

$189.00M

Revenue:

$114.70K

Net Income/Loss:

$-37.06M

P/E Ratio:

-0.9985

EPS:

-3.9929

Net Cash Flow:

$-30.69M

1W Performance:

+1.01%

1M Performance:

+25.47%

6M Performance:

+117.44%

1Y Performance:

+34.34%

1-Day Range:

$3.8075

$4.08

1-Week Range:

$3.58

$4.08

52-Week Range:

$1.00

$6.60

Sab Biotherapeutics Inc Stock (SABS) Company Profile

Name

Sab Biotherapeutics Inc

Sector

Healthcare (1138)

Industry

Biotechnology (632)

Phone

305-845-2813

Address

777 W 41ST ST, MIAMI BEACH

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

SABS's Discussions on Twitter

Compare SABS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SABS Sab Biotherapeutics Inc	3.97	180.91M	114.70K	-37.06M	-30.69M	-3.9929
VRTX Vertex Pharmaceuticals Inc	455.17	116.04B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	720.87	75.97B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	460.00	61.48B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	903.20	56.40B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	204.54	43.73B	447.02M	-1.18B	-906.14M	-6.1812

Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-17-25	Initiated	Leerink Partners	Outperform
May-14-25	Resumed	H.C. Wainwright	Buy
Oct-09-24	Initiated	Craig Hallum	Buy
Aug-28-24	Initiated	Oppenheimer	Outperform
Nov-05-21	Initiated	Chardan Capital Markets	Buy

Sab Biotherapeutics Inc Stock (SABS) Latest News

Dec 04, 2025

Institution Moves: Is Above Food Ingredients Inc. stock safe for conservative investorsNew Guidance & Technical Pattern Based Buy Signals - BỘ NỘI VỤ

Dec 04, 2025

Why analysts upgrade SAB Biotherapeutics Inc. Equity Warrant stockQuarterly Portfolio Review & Safe Swing Trade Setups - Newser

Dec 04, 2025

Will SAB Biotherapeutics Inc. Equity Warrant stock gain from lower inflationMarket Movers & Consistent Growth Equity Picks - Newser

Dec 04, 2025

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Dec 04, 2025

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Dec 04, 2025

Dec 02, 2025

How SAB Biotherapeutics Inc. stock performs in rate cut cyclesWeekly Profit Report & AI Forecast Swing Trade Picks - Newser

Dec 02, 2025

Will SAB Biotherapeutics Inc. Equity Warrant stock reach Wall Street targetsTrade Analysis Report & Daily Volume Surge Signals - Newser

Dec 02, 2025

Is SAB Biotherapeutics Inc. Equity Warrant stock a buy before product launchesEarnings Overview Report & Daily Technical Stock Forecast Reports - Newser

Dec 02, 2025

Nov 27, 2025

Weekly Recap: What margin trends mean for SAB Biotherapeutics Inc. stockMarket Performance Summary & Low Volatility Stock Recommendations - moha.gov.vn

Nov 27, 2025

How SAB Biotherapeutics Inc. Equity Warrant stock trades before earnings2025 EndofYear Setup & Short-Term High Return Strategies - BỘ NỘI VỤ

Nov 27, 2025

The growth track for SAB Biotherapeutics Inc (SABS) has changed recently - Setenews

Nov 27, 2025

Will SAB Biotherapeutics Inc. stock benefit from green energy trendsEarnings Risk Summary & Accurate Entry/Exit Alerts - BỘ NỘI VỤ

Nov 27, 2025

Research Analysts Set Expectations for SABS FY2025 Earnings - Defense World

Nov 27, 2025

Nov 26, 2025

Q1 Earnings Forecast for SABS Issued By Leerink Partnrs - Defense World

Nov 26, 2025

Nov 25, 2025

SAB Biotherapeutics Inc Stock Analysis and ForecastEx-Dividend Date Alerts & Low Cost Stock Picks - earlytimes.in

Nov 25, 2025

Nov 22, 2025

SAB Biotherapeutics, Inc.'s (NASDAQ:SABS) biggest owners are individual investors who got richer after stock soared 22% last week - Yahoo Finance

Nov 22, 2025

SABS Q4 EPS Forecast Lifted by Brookline Capital Management - Defense World

Nov 22, 2025

We Think SAB Biotherapeutics (NASDAQ:SABS) Can Afford To Drive Business Growth - Sahm

Nov 22, 2025

Nov 21, 2025